Sandoz adds 10 biosimilars through $322m Henlius deal
Sandoz adds 10 biosimilars through $322m Henlius deal
Sandoz
Sandoz is a global leader in generic pharmaceuticals and biosimilars, spun off from Novartis in 2023 to focus on off-patent medicines across immunology, oncology, infectious diseases, and metabolic disorders.
Company Info
Sector:Generic pharmaceuticals and biosimilars
Headquarters:Holzkirchen, Bavaria, Germany
Founded:1886
Website:www.sandoz.com/
Recent News
Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars
Latest BioSpace coverage of Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars
Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech
Reuters reports Sandoz will license three biosimilar drugs from Shanghai Henlius Biotech, expanding its biosimilars portfolio.